These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23358608)

  • 1. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.
    Simpson CA; Foer D; Lee GS; Bihuniak J; Sun B; Sullivan R; Belsky J; Insogna KL
    Osteoporos Int; 2014 Oct; 25(10):2383-8. PubMed ID: 24927689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.
    Brabnikova-Maresova K; Jarosova K; Pavelka K; Stepan JJ
    Arthritis Res Ther; 2014 Oct; 16(5):460. PubMed ID: 25280749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes.
    Fazeli PK; Ackerman KE; Pierce L; Guereca G; Bouxsein M; Misra M
    Osteoporos Int; 2013 Sep; 24(9):2433-40. PubMed ID: 23579340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.
    Guañabens N; Gifre L; Peris P
    Curr Osteoporos Rep; 2014 Mar; 12(1):90-7. PubMed ID: 24488619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone.
    Idolazzi L; Fassio A; Tripi G; Braga V; Viapiana O; Adami G; Rossini M; Gatti D
    Clin Rheumatol; 2017 Apr; 36(4):925-928. PubMed ID: 28054306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
    Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
    BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
    Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
    Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients: A Cross-Sectional Study.
    Hsu BG; Liou HH; Lee CJ; Chen YC; Ho GJ; Lee MC
    Medicine (Baltimore); 2016 Apr; 95(15):e3300. PubMed ID: 27082570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
    Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
    Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures.
    Heilmeier U; Carpenter DR; Patsch JM; Harnish R; Joseph GB; Burghardt AJ; Baum T; Schwartz AV; Lang TF; Link TM
    Osteoporos Int; 2015 Apr; 26(4):1283-93. PubMed ID: 25582311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
    Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
    PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
    Ke HZ; Richards WG; Li X; Ominsky MS
    Endocr Rev; 2012 Oct; 33(5):747-83. PubMed ID: 22723594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels.
    Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM
    Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.